QualityCounts.com
Use this link for 5% off at iHerb.
To address the growing use of ad blockers we now use affiliate links to sites like Amazon.com, streaming services, and others. Affiliate links help sites like QualityCounts.com stay open. Affiliate links cost you nothing but help me support my family. We do not allow paid reviews on this site. As an Amazon Associate I earn from qualifying purchases.
Home iHerb ReliableRx Amazon.com Contact
 Sign-up for newsletter 
 Newsletter Archive
 Newsletter via RSS Feed
 Research on Supplements
 Health Conditions
 Anti-aging Recommendations
 Insulin and Aging
 QualityCounts.com in Time
 Longevity Affiliates:
 iHerb
 Canva.com
 Printful (Make your own t-shirt) (video)
 Amazon.com
 T-shirts
 

Home > Health Conditions > Parkinson's > Dostinex (cabergoline)

Dostinex (cabergoline)

Related Topics:

News & Research:

Abstracts:

  • Cabergoline monotherapy in the long-term treatment of Cushing's disease - Eur J Endocrinol. 2010 Aug 11 - "Within 3-6 months, complete response was achieved in 11 patients (36.6%) and partial response in 4 (13.3%). After longer term therapy, 9 patients (30%) remain with a complete response after a mean of 37 months (range from 12-60 months) with a mean dose of 2.1 mg/wk of cabergoline. Two patients escaped after 2 and 5 years of complete response, but one transiently renormalized UFC after an increase in cabergoline dosage. No long-term response was maintained in 4 initial partial responders. Conclusions: Cabergoline monotherapy can provide an effective long-term medical therapy for selected patients with CD, but requires close follow-up for dose adjustments"

Related Searches:

70701